Published in

American Chemical Society, Journal of Medicinal Chemistry, 22(61), p. 10084-10105, 2018

DOI: 10.1021/acs.jmedchem.8b01262

Links

Tools

Export citation

Search in Google Scholar

Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders

Journal article published in 2018 by Denise Rageot ORCID, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari ORCID, Petra Hillmann, Alexander M. Sele ORCID, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John Burke ORCID, Doriano Fabbro, Matthias P. Wymann ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
  • Must obtain written permission from Editor
  • Must not violate ACS ethical Guidelines
Upload
Orange circle
Postprint: archiving restricted
  • Must obtain written permission from Editor
  • Must not violate ACS ethical Guidelines
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO